BDSX - Biodesix Inc Stock Price, Fair Value and News

$7.95-0.07 (-0.87%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

BDSX Price Action

Last 7 days

-6.6%

Last 30 days

-4.3%

Last 90 days

6.4%

Trailing 12 Months

-69.3%

BDSX RSI Chart

BDSX Valuation

Market Cap

63.2M

Price/Earnings (Trailing)

-1.6

Price/Sales (Trailing)

0.79

Price/Free Cashflow

-2.17

BDSX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

BDSX Fundamentals

BDSX Revenue

Revenue (TTM)

80.2M

Rev. Growth (Yr)

19.93%

Rev. Growth (Qtr)

8.74%

BDSX Earnings

Earnings (TTM)

-39.5M

Earnings Growth (Yr)

15.03%

Earnings Growth (Qtr)

24%

BDSX Profitability

Return on Equity

2.3K%

Return on Assets

-44.56%

Free Cashflow Yield

-46.1%

BDSX Investor Care

Shares Dilution (1Y)

9.38%

Diluted EPS (TTM)

-5.25

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	74.5M	76.6M	80.2M	0
2024	54.8M	60.9M	65.6M	71.3M
2023	40.7M	41.6M	44.0M	49.1M
2022	32.2M	31.3M	35.8M	38.2M
2021	69.3M	77.0M	74.3M	54.5M
2020	29.8M	35.1M	40.3M	45.6M
2019	0	0	0	24.6M

Get all data in R, Python etc through our Historical Stock Data APIs

About Biodesix Inc

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a blood-based NGS. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.

CEO	Mr. Scott Hutton
WEBSITE	biodesix.com
SECTOR	Healthcare
INDUSTRY	Diagnostics & Research
EMPLOYEES	245

Biodesix Inc Frequently Asked Questions

What is the ticker symbol for Biodesix Inc? What does BDSX stand for in stocks?

BDSX is the stock ticker symbol of Biodesix Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Biodesix Inc (BDSX)?

As of Thu Dec 11 2025, market cap of Biodesix Inc is 63.49 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BDSX stock?

You can check BDSX's fair value in chart for subscribers.

Is Biodesix Inc a good stock to buy?

The fair value guage provides a quick view whether BDSX is over valued or under valued. Whether Biodesix Inc is cheap or expensive depends on the assumptions which impact Biodesix Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BDSX.

What is Biodesix Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Dec 11 2025, BDSX's PE ratio (Price to Earnings) is -1.61 and Price to Sales (PS) ratio is 0.79. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BDSX PE ratio will change depending on the future growth rate expectations of investors.